Sonoma Biotherapeutics
About Sonoma Biotherapeutics
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy and built on Nobel-winning research, the company is evaluating its lead Treg program in clinical trials, targeting conditions such as rheumatoid arthritis and hidradenitis suppurativa.
Company details
Funding
Total raised
$335M
Last stage
Series B
Investors
Founders
Jeffrey Bluestone
One of the leading immunologists in T-cell activation and immune tolerance research. Co-founded Sonoma Biotherapeutics and served as its President and CEO before transitioning to Advisor and Board Member in November 2025. Previously President and CEO of the Parker Institute for Cancer Immunotherapy.
LinkedInFred Ramsdell
Veteran biotechnology leader in immunology with nearly three decades of experience. Led the team that discovered and characterized FoxP3, a gene critical to regulatory T cell function. Previously CSO at the Parker Institute for Cancer Immunotherapy.
Alexander Rudensky
Co-founder of Sonoma Biotherapeutics and leading researcher in regulatory T cell biology.
Qizhi Tang
Co-founder of Sonoma Biotherapeutics, recognized as a pioneer in Treg biology and cell therapy.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.